Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Cost of RevenueDepreciation ExpenseEBIATGross ProfitLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsReceivables - NetReceivables - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

Akebia Therapeutics (AKBA) Leases (2019 - 2026)

Akebia Therapeutics has reported Leases over the past 7 years, most recently at $3.7 million for Q4 2025.

  • Quarterly Leases fell 55.43% to $3.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $3.7 million through Dec 2025, down 55.43% year-over-year, with the annual reading at $3.7 million for FY2025, 55.43% down from the prior year.
  • Leases was $3.7 million for Q4 2025 at Akebia Therapeutics, down from $4.8 million in the prior quarter.
  • Over five years, Leases peaked at $33.9 million in Q4 2021 and troughed at $3.7 million in Q4 2025.
  • The 5-year median for Leases is $13.9 million (2023), against an average of $18.0 million.
  • Year-over-year, Leases soared 30.81% in 2022 and then tumbled 59.23% in 2024.
  • A 5-year view of Leases shows it stood at $33.9 million in 2021, then fell by 13.87% to $29.2 million in 2022, then plummeted by 57.42% to $12.4 million in 2023, then tumbled by 33.81% to $8.2 million in 2024, then tumbled by 55.43% to $3.7 million in 2025.
  • Per Business Quant, the three most recent readings for AKBA's Leases are $3.7 million (Q4 2025), $4.8 million (Q3 2025), and $6.0 million (Q2 2025).